BCAT1 and neoplasm: More importantly, LY294002, an inhibitor of the PI3K/AKT/mTOR pathway, markedly reversed BCAT1-mediated tumorigenicity, including the phosphorylation of AKT; increased cell viability, proliferation, invasion, and angiogenesis; and tumor growth.